[
    {
        "id": 5260,
        "drug_name": "DARZALEX (Daratumumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Newly Diagnosed Multiple Myeloma (NDMM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-28",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/581becf2-60d2-4ab0-a94f-a35c8b24eb49",
        "note": "FDA Approval announced June 28, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5260,
        "drug_name": "DARZALEX (Daratumumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Newly Diagnosed Multiple Myeloma (NDMM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-06-28",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/581becf2-60d2-4ab0-a94f-a35c8b24eb49",
        "note": "FDA Approval announced June 28, 2019.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3612,
        "drug_name": "XPOVIO (selinexor)",
        "clinical_trial_id": "NCT02336815",
        "has_trial_insight_page": 0,
        "indication": "Quadruple Refractory Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-07-03",
        "link": "https:\/\/investors.karyopharm.com\/news-releases\/news-release-details\/karyopharm-announces-fda-approval-xpoviotm-selinexor-treatment",
        "note": "FDA Approval announced July 3, 2019. Continued approval may be contingent upon data from its Phase 3 Boston trial (data due late-2019\/early 2020).",
        "company_entity_id": 183,
        "company_ticker": "KPTI",
        "company_name": "Karyopharm Therapeutics Inc.",
        "company_price": "1.4500",
        "company_change": -0.030000000000000027,
        "company_percent_change": -2.0300000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 115067083,
        "price_change_sparkline": [
            [
                0.7505,
                1706677200
            ],
            [
                0.9003,
                1706763600
            ],
            [
                1.04,
                1706850000
            ],
            [
                1.35,
                1707109200
            ],
            [
                1.66,
                1707195600
            ],
            [
                1.525,
                1707282000
            ],
            [
                1.51,
                1707368400
            ],
            [
                1.34,
                1707454800
            ],
            [
                1.3,
                1707714000
            ],
            [
                1.285,
                1707800400
            ],
            [
                1.36,
                1707886800
            ],
            [
                1.3,
                1707973200
            ],
            [
                1.27,
                1708059600
            ],
            [
                1.21,
                1708405200
            ],
            [
                1.21,
                1708491600
            ],
            [
                1.13,
                1708578000
            ],
            [
                1.24,
                1708664400
            ],
            [
                1.31,
                1708923600
            ],
            [
                1.41,
                1709010000
            ],
            [
                1.33,
                1709096400
            ],
            [
                1.16,
                1709182800
            ],
            [
                1.185,
                1709269200
            ],
            [
                1.31,
                1709528400
            ],
            [
                1.245,
                1709614800
            ],
            [
                1.33,
                1709701200
            ],
            [
                1.53,
                1709787600
            ],
            [
                1.57,
                1709874000
            ],
            [
                1.48,
                1710129600
            ],
            [
                1.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5469,
        "drug_name": "PRIMAXIN (imipenem and cilastatin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-07-17",
        "link": "http:\/\/bit.ly\/2GiNK9N",
        "note": "FDA Approval announced July 17, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2922,
        "drug_name": "OTEZLA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Beh\u00e7et\u2019s Disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-07-19",
        "link": "https:\/\/ir.celgene.com\/press-releases\/press-release-details\/2019\/FDA-Approves-OTEZLA-apremilast-for-the-Treatment-of-Oral-Ulcers-Associated-with-Behets-Disease\/default.aspx",
        "note": "FDA Approval announced July 19, 2019.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5938,
        "drug_name": "RUXIENCE (Biosimilar to Rituxan)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "CD20-positive, low tumor burden, follicular lymphoma.",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-07-23",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions",
        "note": "FDA approval announced July 23, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5949,
        "drug_name": "BAQSIMI (glucagon)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Severe hypoglycemia in people with diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-07-24",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally",
        "note": "FDA Approval announced July 24, 2019.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5177,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "NCT02564263",
        "has_trial_insight_page": 0,
        "indication": "Esophageal Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-07-31",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-New-Monotherapy-Indication-for-Mercks-KEYTRUDA-pembrolizumab\/default.aspx",
        "note": "FDA Approval announced July 31, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6047,
        "drug_name": "ROZLYTREK (entrectinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Solid tumors - NTRK gene fusion",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-08-15",
        "link": "http:\/\/bit.ly\/2YOPlQ1",
        "note": "FDA approval announced August 15, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3769,
        "drug_name": "ROZLYTREK (entrectinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-08-15",
        "link": "http:\/\/bit.ly\/2YOPlQ1",
        "note": "FDA approval announced August 15, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5454,
        "drug_name": "Fedratinib",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Myelofibrosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-08-16",
        "link": "https:\/\/ir.celgene.com\/press-releases\/press-release-details\/2019\/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis\/default.aspx",
        "note": "FDA Approval announced August 16, 2019.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4679,
        "drug_name": "RINVOQ (Upadacitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Rheumatoid arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-08-16",
        "link": "https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm?view_id=822",
        "note": "FDA Approval announced August 16, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3655,
        "drug_name": "XENLETA (lefamulin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Moderate to severe Community Acquired Bacterial Pneumonia (CABP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-08-19",
        "link": "https:\/\/investors.nabriva.com\/news-releases\/news-release-details\/nabriva-therapeutics-receives-us-fda-approval-xenleta",
        "note": "FDA approval announced August 19, 2019.",
        "company_entity_id": 206,
        "company_ticker": "NBRV",
        "company_name": "Nabriva Therapeutics plc",
        "company_price": "1.4200",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 3200000,
        "price_change_sparkline": [
            [
                1.0e-6,
                1706677200
            ],
            [
                0.0003,
                1706763600
            ],
            [
                0.0002,
                1706850000
            ],
            [
                0.0002,
                1707109200
            ],
            [
                0.0002,
                1707195600
            ],
            [
                0.0002,
                1707282000
            ],
            [
                0.0002,
                1707368400
            ],
            [
                0.0002,
                1707454800
            ],
            [
                0.0002,
                1707714000
            ],
            [
                0.0002,
                1707800400
            ],
            [
                0.0002,
                1707886800
            ],
            [
                0.0002,
                1707973200
            ],
            [
                0.0002,
                1708059600
            ],
            [
                0.0002,
                1708405200
            ],
            [
                0.0002,
                1708491600
            ],
            [
                0.0002,
                1708578000
            ],
            [
                0.0002,
                1708664400
            ],
            [
                0.0002,
                1708923600
            ],
            [
                0.0002,
                1709010000
            ],
            [
                0.0002,
                1709096400
            ],
            [
                0.0002,
                1709182800
            ],
            [
                0.0002,
                1709269200
            ],
            [
                0.0002,
                1709528400
            ],
            [
                0.0002,
                1709614800
            ],
            [
                0.0002,
                1709701200
            ],
            [
                0.0002,
                1709787600
            ],
            [
                0.0002,
                1709874000
            ],
            [
                0.0002,
                1710129600
            ]
        ],
        "statuses": []
    },
    {
        "id": 4476,
        "drug_name": "TALTZ (ixekizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Axial Spondyloarthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-08-26",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-receives-us-fda-approval-taltzr-ixekizumab-treatment",
        "note": "FDA Approval announced August 26, 2019.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6057,
        "drug_name": "JUV\u00c9DERM VOLUMA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Mid-Face Injection Via Cannula",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-03",
        "link": "https:\/\/www.allergan.com\/News\/News\/Thomson-Reuters\/Allergan-Receives-FDA-Approval-of-Juv-derm-VOLUMA",
        "note": "FDA Approval announced September 3, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4919,
        "drug_name": "Glucagon Rescue Pen",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Severe hypoglycemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-10",
        "link": "https:\/\/investors.xerispharma.com\/news-releases\/news-release-details\/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon",
        "note": "FDA Approval issued September 10, 2019.",
        "company_entity_id": 562,
        "company_ticker": "XERS",
        "company_name": "Xeris Biopharma Holdings Inc.",
        "company_price": "2.2100",
        "company_change": -0.040000000000000036,
        "company_percent_change": -1.78,
        "company_optionable": 1,
        "company_number_of_shares": 140453467,
        "price_change_sparkline": [
            [
                2.46,
                1706677200
            ],
            [
                2.51,
                1706763600
            ],
            [
                2.45,
                1706850000
            ],
            [
                2.47,
                1707109200
            ],
            [
                2.64,
                1707195600
            ],
            [
                2.63,
                1707282000
            ],
            [
                2.73,
                1707368400
            ],
            [
                2.87,
                1707454800
            ],
            [
                2.95,
                1707714000
            ],
            [
                2.87,
                1707800400
            ],
            [
                3.21,
                1707886800
            ],
            [
                3.21,
                1707973200
            ],
            [
                3.22,
                1708059600
            ],
            [
                3.16,
                1708405200
            ],
            [
                3,
                1708491600
            ],
            [
                3.04,
                1708578000
            ],
            [
                3.01,
                1708664400
            ],
            [
                3.11,
                1708923600
            ],
            [
                3.13,
                1709010000
            ],
            [
                3.02,
                1709096400
            ],
            [
                3.075,
                1709182800
            ],
            [
                3.18,
                1709269200
            ],
            [
                3.04,
                1709528400
            ],
            [
                3.08,
                1709614800
            ],
            [
                2.48,
                1709701200
            ],
            [
                2.44,
                1709787600
            ],
            [
                2.35,
                1709874000
            ],
            [
                2.25,
                1710129600
            ],
            [
                2.21,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6070,
        "drug_name": "NUCALA (Mepolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Severe eosinophilic asthma (6-11 yrs)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-12",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma\/",
        "note": "FDA approval announced September 12, 2019.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2614,
        "drug_name": "Tenapanor (T3MPO-2)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Constipation-predominant irritable bowel syndrome (IBS-C) ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-12",
        "link": "http:\/\/ir.ardelyx.com\/news-releases\/news-release-details\/ardelyx-receives-fda-approval-ibsrelar-tenapanor-nhe3-sodium",
        "note": "FDA approval announced September 12, 2019.",
        "company_entity_id": 41,
        "company_ticker": "ARDX",
        "company_name": "Ardelyx Inc.",
        "company_price": "8.4200",
        "company_change": -0.06999999999999995,
        "company_percent_change": -0.8200000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 232686008,
        "price_change_sparkline": [
            [
                8.73,
                1706677200
            ],
            [
                9.29,
                1706763600
            ],
            [
                8.89,
                1706850000
            ],
            [
                8.96,
                1707109200
            ],
            [
                9.12,
                1707195600
            ],
            [
                8.97,
                1707282000
            ],
            [
                9.27,
                1707368400
            ],
            [
                9.74,
                1707454800
            ],
            [
                9.73,
                1707714000
            ],
            [
                8.86,
                1707800400
            ],
            [
                9.28,
                1707886800
            ],
            [
                9.3,
                1707973200
            ],
            [
                9.04,
                1708059600
            ],
            [
                8.55,
                1708405200
            ],
            [
                8.5,
                1708491600
            ],
            [
                8.82,
                1708578000
            ],
            [
                8.68,
                1708664400
            ],
            [
                9.29,
                1708923600
            ],
            [
                9.67,
                1709010000
            ],
            [
                9.46,
                1709096400
            ],
            [
                9.32,
                1709182800
            ],
            [
                9.34,
                1709269200
            ],
            [
                9.04,
                1709528400
            ],
            [
                9.59,
                1709614800
            ],
            [
                9.53,
                1709701200
            ],
            [
                8.97,
                1709787600
            ],
            [
                8.69,
                1709874000
            ],
            [
                8.49,
                1710129600
            ],
            [
                8.42,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6079,
        "drug_name": "KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Endometrial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-17",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-KEYTRUDA-pembrolizumab-plus-LENVIMA-lenvatinib-Combination-Treatment-for-Patients-with-Certain-Types-of-Endometrial-Carcinoma\/default.aspx",
        "note": "FDA Approval announced September 17, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5448,
        "drug_name": "ERLEADA (apalutamide)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Metastatic castration-sensitive prostate cancer (mCSPC).",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-18",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/f553c9f8-3a12-43a8-ab94-6408a435d3e2",
        "note": "FDA Approval announced September 18, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 1945,
        "drug_name": "OZEMPIC (semaglutide)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Type 2 diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-20",
        "link": "https:\/\/www.novonordisk.com\/media\/news-details.2172050.html",
        "note": "FDA approval announced September 20, 2019.",
        "company_entity_id": 385,
        "company_ticker": "NVO",
        "company_name": "Novo Nordisk A\/S",
        "company_price": "135.1100",
        "company_change": 3.87,
        "company_percent_change": 2.95,
        "company_optionable": 1,
        "company_number_of_shares": 4510000000,
        "price_change_sparkline": [
            [
                114.74,
                1706677200
            ],
            [
                115.79,
                1706763600
            ],
            [
                113.7,
                1706850000
            ],
            [
                118.26,
                1707109200
            ],
            [
                117.61,
                1707195600
            ],
            [
                118.66,
                1707282000
            ],
            [
                118.39,
                1707368400
            ],
            [
                121.2,
                1707454800
            ],
            [
                120.53,
                1707714000
            ],
            [
                119.99,
                1707800400
            ],
            [
                123.29,
                1707886800
            ],
            [
                121.75,
                1707973200
            ],
            [
                124.01,
                1708059600
            ],
            [
                121.45,
                1708405200
            ],
            [
                120.93,
                1708491600
            ],
            [
                124.52,
                1708578000
            ],
            [
                123.45,
                1708664400
            ],
            [
                123.49,
                1708923600
            ],
            [
                122.23,
                1709010000
            ],
            [
                121.54,
                1709096400
            ],
            [
                119.77,
                1709182800
            ],
            [
                124.23,
                1709269200
            ],
            [
                127.95,
                1709528400
            ],
            [
                124.65,
                1709614800
            ],
            [
                124.75,
                1709701200
            ],
            [
                135.92,
                1709787600
            ],
            [
                133.07,
                1709874000
            ],
            [
                131.24,
                1710129600
            ],
            [
                135.11,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5424,
        "drug_name": "DELSTRIGO (doravirine\/lamivudine\/tenofovir disoproxil fumarate)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-20",
        "link": "http:\/\/bit.ly\/2mpSnrv",
        "note": "FDA Approval for sNDA announced September 20, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5617,
        "drug_name": "DARZALEX (Daratumumab) + bortezomib, thalidomide and dexamethasone (VTd)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma - candidates for autologous stem cell transplant (ASCT)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-26",
        "link": "https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-us-fda-approval-darzalexr-daratumumab-1",
        "note": "FDA Approval announced September 26, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5617,
        "drug_name": "DARZALEX (Daratumumab) + bortezomib, thalidomide and dexamethasone (VTd)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma - candidates for autologous stem cell transplant (ASCT)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-09-26",
        "link": "https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-us-fda-approval-darzalexr-daratumumab-1",
        "note": "FDA Approval announced September 26, 2019.",
        "company_entity_id": 684,
        "company_ticker": "GMAB",
        "company_name": "Genmab A\/S",
        "company_price": "31.4300",
        "company_change": -0.25,
        "company_percent_change": -0.79,
        "company_optionable": 1,
        "company_number_of_shares": 660745350,
        "price_change_sparkline": [
            [
                27.61,
                1706677200
            ],
            [
                28.17,
                1706763600
            ],
            [
                27.8,
                1706850000
            ],
            [
                27.57,
                1707109200
            ],
            [
                28.15,
                1707195600
            ],
            [
                27.97,
                1707282000
            ],
            [
                27.79,
                1707368400
            ],
            [
                27.84,
                1707454800
            ],
            [
                27.49,
                1707714000
            ],
            [
                26.43,
                1707800400
            ],
            [
                27.59,
                1707886800
            ],
            [
                28.23,
                1707973200
            ],
            [
                28.71,
                1708059600
            ],
            [
                28.95,
                1708405200
            ],
            [
                28.95,
                1708491600
            ],
            [
                29.11,
                1708578000
            ],
            [
                29.16,
                1708664400
            ],
            [
                29.4,
                1708923600
            ],
            [
                29.05,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.77,
                1709182800
            ],
            [
                29.29,
                1709269200
            ],
            [
                28.51,
                1709528400
            ],
            [
                28.75,
                1709614800
            ],
            [
                28.86,
                1709701200
            ],
            [
                29.41,
                1709787600
            ],
            [
                30.3,
                1709874000
            ],
            [
                31.68,
                1710129600
            ],
            [
                31.43,
                1710216000
            ]
        ],
        "statuses": []
    }
]